Tuberculosis control: Past 10 years and future progress

Tuberculosis

Volumn 83, Issue 1-3, 2003, Pages 82-85

  Frieden, Thomas R ^a   Driver, Cynthia R ^a  

^a NEW YORK CITY DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; GOVERNMENT; HEALTH CARE; HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SHORT COURSE THERAPY; TUBERCULOSIS;

EID: 0038182031     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(02)00060-4     Document Type: Conference Paper

References (17)

1. World Health Organization. Global DOTS expansion plan: progress in TB control in high-burden countries. 2001: WHO/CDS/STB/2001.11.
2. Suarez PG, Watt CJ, Alarcon E, et al. The dynamics of tuberculosis in response to 10 years of intensive control effort in Peru. J Infect Dis 2001;184:473-8.
3. Chen X, Zhao F, Duanmu H, Wan L, Du X, Chin D. The DOTS strategy in China: results and lessons after 10 years. Bull WHO 2002;80:430-6.
4. Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City turning the tide. N Engl J Med 1995;333:229-33.
5. Jasmer RM, Hahn JA, Small PM, et al. A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997. Ann Intern Med 1999;130:971-8.
6. Dye C, Watt C, Bleed D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull WHO 2002;80:430-6.
7. Blower SM, Daley CL. Problems and solutions for the Stop TB partnership. Lancet Infect Dis 2002;2:374-6.
8. Chaulk PC, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: consensus statement of the public health tuberculosis guidelines panel. JAMA 1998;279:943-8.
9. Alwood K, Keruly J, Moore Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS 1994;8:1103-8.
10. Alpert PL, Munsiff SS, Gourevitch MN, et al. A prospective study of tuberculosis and human immunodeficiency virus infection: clinical manifestations and factors associated with survival. Clin Infect Dis 1997;24:661-8.
11. Raviglione MC, Pio A. Evolution of WHO policies for tuberculosis control, 1948-2001. Lancet 2002;359:775-80.
12. Frieden TR, Lerner BH, Rutherford BR. Lessons from the 1800s: tuberculosis control in the new millennium. Lancet 2000;355:1088-92.
13. Espinal MA, Laszlo A, Simonsen L, et al. GLobal trends in resistance to antituberculosis drugs. N Engl J Med 2001;344:1294-303.
14. Sterling TR, Lehmann HP, Frieden TR. The impact of directly observed therapy short-course (DOTS) vs. DOTS-Plus on multidrug-resistant tuberculosis: decision analysis. Am J Resp Crit Care Med 2001;163:A497.
15. Dholakia R, Almeida J. The potential economic benefits of the DOTS strategy against TB in India, Geneva: World Health Organization, 1997: WHO/TB/96.218.
16. Sawert H, et al. Costs and benefits of improving tuberculosis control: the case of thailand. Soc Sci Med 1997;44:1805-16.
17. WHO. Joint programme review: India. New Delhi: World Health Organization, 2000: WHO/SEA/TB/2000.224.